1.59
Precedente Chiudi:
$1.58
Aprire:
$1.55
Volume 24 ore:
1.01M
Relative Volume:
0.89
Capitalizzazione di mercato:
$97.60M
Reddito:
$5.03M
Utile/perdita netta:
$-185.41M
Rapporto P/E:
-0.5146
EPS:
-3.09
Flusso di cassa netto:
$-139.79M
1 W Prestazione:
+11.97%
1M Prestazione:
+22.31%
6M Prestazione:
-85.44%
1 anno Prestazione:
-87.47%
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Nome
Pliant Therapeutics Inc
Settore
Industria
Telefono
650-481-6770
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta PLRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PLRX
Pliant Therapeutics Inc
|
1.59 | 96.99M | 5.03M | -185.41M | -139.79M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-04 | Ripresa | Cantor Fitzgerald | Neutral |
2025-03-04 | Downgrade | Needham | Buy → Hold |
2025-03-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
2025-03-03 | Downgrade | Stifel | Buy → Hold |
2025-02-10 | Downgrade | Canaccord Genuity | Buy → Hold |
2025-02-10 | Downgrade | Citigroup | Buy → Neutral |
2025-02-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
2025-02-10 | Downgrade | JP Morgan | Overweight → Neutral |
2025-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
2025-02-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-09-09 | Ripresa | Leerink Partners | Outperform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2023-05-18 | Iniziato | Canaccord Genuity | Buy |
2023-04-13 | Iniziato | Robert W. Baird | Outperform |
2022-12-14 | Iniziato | Stifel | Buy |
2022-12-07 | Iniziato | JP Morgan | Overweight |
2022-09-01 | Iniziato | Citigroup | Buy |
2022-07-20 | Iniziato | SVB Leerink | Outperform |
2022-05-25 | Iniziato | Cantor Fitzgerald | Overweight |
2021-12-10 | Iniziato | Oppenheimer | Outperform |
2021-11-24 | Iniziato | RBC Capital Mkts | Outperform |
2021-11-03 | Iniziato | H.C. Wainwright | Buy |
2021-04-20 | Iniziato | BTIG Research | Buy |
2021-04-05 | Iniziato | Citigroup | Buy |
2020-06-29 | Iniziato | Citigroup | Buy |
2020-06-29 | Iniziato | Cowen | Outperform |
2020-06-29 | Iniziato | Needham | Buy |
2020-06-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie
What analysts say about Pliant Therapeutics Inc. stockOutperformance with explosive growth - jammulinksnews.com
What drives Pliant Therapeutics Inc. stock priceAccelerated wealth expansion - Autocar Professional
Pliant Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com
Is Pliant Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
Is Pliant Therapeutics Inc. stock a growth or value playHigh Return Potential - Newser
What makes Pliant Therapeutics Inc. stock price move sharplyDefensive Stock Picks with Upside - Newser
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
How Pliant Therapeutics Inc. stock performs during market volatilityTrade Ready Signal - Newser
Why Pliant Therapeutics Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - Newser
Pliant Therapeutics Inc (PLRX) Stock: Navigating a Year of Volatility - investchronicle.com
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN) - The Globe and Mail
Pliant Therapeutics, Inc.(NasdaqGS: PLRX) dropped from Russell 2500 Index - MarketScreener
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - The Manila Times
Pliant Therapeutics Provides Update on BEACON-IPF | PLRX Stock News - GuruFocus
Pliant Therapeutics Provides Update on BEACON-IPF - GlobeNewswire
Pliant Therapeutics Provides Update on BEACON-IPF | PLRX Stock N - GuruFocus
Pliant Therapeutics Inc’s (PLRX) Stock Is Harder To Predict Than You Think - Stocksregister
Pliant Therapeutics amends corporate bylaws, holds stockholder vote By Investing.com - Investing.com Nigeria
Pliant Therapeutics amends corporate bylaws, holds stockholder vote - Investing.com
Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada
Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus
Pliant Therapeutics presents new fibrosis treatment data - Investing.com
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire
How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister
Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks
Another Bay Area biotech company announces layoffs - MSN
Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - The Manila Times
Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):